Intermittent chemotherapy in metastatic androgen-independent prostate cancer

BJU International

Volumn 100, Issue 3, 2007, Pages 490-492

  Bellmunt, Joaquim ^a   Albiol, Santiago ^a   Albanell, Joan ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; DOCETAXEL; ESTRAMUSTINE;

ASTHENIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CYTOPENIA; DRUG EFFICACY; DRUG SAFETY; EDEMA; HUMAN; NOTE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; QUESTIONNAIRE; TREATMENT DURATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SURVIVAL ANALYSIS;

EID: 34547633091     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07058.x     Document Type: Note

References (15)

1. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004 351 : 1502 12
2. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004 351 : 1513 20
3. Tormey DC, Weinberg VE, Leone LA et al. A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer. A Cancer and Leukemia Group B Study. Am J Clin Oncol 1984 7 : 231 9
4. Coates A, Gebski V, Bishop JF et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 1987 317 : 1490 5
5. Muss HB, Case LD, Richards F Jr. et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med 1991 325 : 1342 8
6. Anonymous. Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment. J Clin Oncol 2000 18 : 3115 24
7. Maughan TS, James RD, Kerr DJ et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet 2003 361 : 457 64
8. Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM. Intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer 2003 89 : 968 70
9. Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM. Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer 2004 91 : 1425 7
10. Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD. Weekly high-dose calcitriol and docetaxel in metastatic androgen independent prostate cancer. J Clin Oncol 2003 21 : 123 8
11. Bubley GJ, Carducci M. DahutW et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999 17 : 3461 7
12. Beer TM, Ryan CW, Venner P et al. Intermittent chemotherapy in metastatic androgen-independent prostate cancer (AIPC): initial results from ASCENT. Proceedings of the American Society of Clinical Oncology Multi-Disciplinary Prostate Cancer Symposium 2006 : Abstract 216
13. Beer TM, Ryan CW, Venner PM et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 2007 25 : 669 74
14. Miller K, Wulfing C, Lehmann J et al. Weekly docetaxel plus estramustine for hormone-refractory prostate cancer (HRPC) with intermittent repetition. preliminary results of a multicenter phase II study (AUO AP33/02). Proc American Society of Clinical Oncology 2005 : Abstract 4613
15. Lin AM, Ryan CJ, Small EJ. Intermittent chemotherapy for metastatic hormone refractory prostate cancer. Crit Rev Oncol Hematol 2007 61 : 243 54